First Header Logo Second Header Logo

Connection

William Lowther to Enzyme Inhibitors

This is a "connection" page, showing publications William Lowther has written about Enzyme Inhibitors.
Connection Strength

0.497
  1. Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007 Aug; 14(8):704-9.
    View in: PubMed
    Score: 0.277
  2. Summitt CB, Johnson LC, Jönsson TJ, Parsonage D, Holmes RP, Lowther WT. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. Biochem J. 2015 Mar 01; 466(2):273-81.
    View in: PubMed
    Score: 0.118
  3. Murray MS, Holmes RP, Lowther WT. Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. Biochemistry. 2008 Feb 26; 47(8):2439-49.
    View in: PubMed
    Score: 0.072
  4. Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines. Mol Pharm. 2016 Mar 07; 13(3):720-8.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.